Physician profile
Lisa Coco
NPI 1841203726
$229,561.03
in general payments reported to CMS, 2019-2025
35 companies · $42K in 2025
The $42K reported for 2025 was more than what 99% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $80K · 2022: $64K · 2023: $30K · 2024: $12K · 2025: $42K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Honoraria: $12K · Travel and Lodging: $12K · Consulting Fee: $9,259 · Food and Beverage: $6,476 · Long Term Medical Supply Or Device Loan: $59.94 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $44,138.01 |
| Honoraria | $12,444.94 |
| Travel and Lodging | $12,384.09 |
| Consulting Fee | $9,258.75 |
| Food and Beverage | $6,476.45 |
| Long Term Medical Supply Or Device Loan | $59.94 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $164,640.57 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Xeris Pharmaceuticals, INC. | $32,517.63 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Astrazeneca Pharmaceuticals LP | $17,101.17 | 2021-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $8,989.75 | 2021-2024 | |
| Glaxosmithkline, LLC. | $2,560.88 | 2025 | Arexvy, Shingrix |
| Amgen INC. | $880.39 | 2021-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $655.36 | 2022-2025 | Freestyle Libre 3, Freestyle Insulinx |
| Lilly USA, LLC | $327.09 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $325.46 | 2021-2023 | |
| Amarin Pharma, INC. | $267.77 | 2021-2022 | |
| Corcept Therapeutics | $200.68 | 2023-2025 | Korlym |
| Medtronic, INC. | $139.31 | 2023-2025 | Minimed 780g |
| Ascendis Pharma Endocrinology INC | $139.07 | 2025 | Yorvipath |
| Amphastar Pharmaceuticals, INC. | $124.74 | 2023-2025 | Baqsimi |
| Mannkind Corporation | $74.28 | 2021-2023 | Afrezza |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $63.32 | 2021-2025 | |
| Radius Health, INC. | $57.31 | 2021-2023 | Tymlos |
| Amryt Pharma Holdings LTD | $46.29 | 2023 | Myalept |
| Alexion Pharmaceuticals, INC. | $34.99 | 2025 | Strensiq |
| Esperion Therapeutics, INC. | $34.40 | 2025 | Nexletol |
| Neurocrine Biosciences, INC. | $33.53 | 2025 | |
| Grt US Holding, INC. | $33.16 | 2022 | |
| Recordati_rare_diseases_inc. | $31.60 | 2024 | Signifor Lar, Isturisa |
| Cequr Corporation | $31.17 | 2025 | Cequr Simplicity |
| Tolmar, INC. | $30.01 | 2024-2025 | Jatenzo |
| Lifescan, INC. | $29.61 | 2022 | |
| Dexcom, INC. | $29.33 | 2024 | Dexcom G6 Transmitter |
| Ascensia Diabetes Care US INC. | $26.15 | 2024 | |
| Averitas Pharma INC. | $24.76 | 2025 | Qutenza |
| Novartis Pharmaceuticals Corporation | $24.19 | 2023 | |
| Tandem Diabetes Care, INC. | $21.63 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Azurity Pharmaceuticals, INC. | $17.15 | 2025 | Azmiro |
| Rhythm Pharmaceuticals, INC. | $16.91 | 2025 | Imcivree |
| Clarus Therapeutics INC. | $16.37 | 2021 | |
| Acerus Pharmaceuticals Corporation | $15.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Coco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.